SBC Medical Group Holdings Announces First Quarter 2026 Financial Results

14.5.2026 12:30:00 CEST | Business Wire | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced its financial results for the three months ended March 31, 2026.

First Quarter 2026 Highlights

Total revenues were $43 million, representing a 9% year-over-year decrease.
Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, representing a 47% year-over-year decrease. Net income margin was 26% for the first quarter of 2026, representing a year-over-year decrease of 19 percentage points.
Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.11 for the three months ended March 31, 2026, representing a 48% year-over-year decrease.
EBITDA¹, which is calculated by adding depreciation and amortization expense to income from operations was $18 million, representing a 26% year-over-year decrease. EBITDA margin¹was 43% for the first quarter of 2026, representing a year-over-year decrease of 10 percentage points.
Return on equity², which is defined as net income attributable to the Company divided by the average shareholders' equity as of March 31, 2026, was 18% representing a year-over-year decrease of 23 percentage points.
Number of franchise locations³was 284 as of March 31, 2026, representing an increase of 33 locations from March 31, 2025.
Number of customers⁴in the last twelve months ended March 31, 2026, was 6.76 million, representing a 10% year-over-year increase.
Repeat rate for customers⁵who visited franchisee’s clinics twice or more was 72%.

Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, “For the first quarter of fiscal year 2026, SBC Medical reported revenue of $43 million, representing a 9% year-over-year decline. This decrease was primarily attributable to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure. Excluding this structural change, the performance of our core business remained solid. In terms of profitability, our net income margin was 26%, and our EBITDA margin remained at a high level of 43%.

Looking ahead, we will continue to promote our multi-brand strategy in the aesthetic dermatology field, expand our non-aesthetic medical business, and strengthen our operational foundation in overseas markets. In addition, we will pursue opportunities in the longevity market and further enhance our services through the utilization of AI, with the goal of building a sustainable and continuously growing healthcare platform.”


¹EBITDA and EBITDA margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section “Use of Non-GAAP Financial Measures” and the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”
²Return on equity is presented on an annualized basis.
³ The figure includes locations of the franchising of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, JUN CLINIC, OrangeTwist.
⁴ The customer count includes customers of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, and JUN CLINIC. The applicable periods are from April 1, 2025 to March 31, 2026.
⁵ The figures include franchised SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, and JUN Clinic, excluding free counseling. The percentages represent customers who visited our franchisees' clinics twice or more. Please note that the unique counts and repeat rates for AHH clinics and JUN clinics are estimated based on the ratios of SBC brand clinics, Rize clinics, and Gorilla clinics.

Conference Call

The Company will hold a conference call on Thursday, May 14, 2026, at 8:30 a.m. Eastern Time (or Thursday, May 14, 2026, at 9:30 p.m. Japan Time) to discuss the financial results for the first quarter ended March 31, 2026. A question‑and‑answer session with analysts and investors will follow the prepared remarks.

Please register in advance of the conference using the link provided below. https://zoom.us/webinar/register/WN_6RZgrwsUREiRpAmBBGTikA

It will automatically direct you to the registration page of “ 1Q 2026 Earning Call ”. Please follow the steps to enter your registration details, then click “Submit.”. Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past investor relations materials.

Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company’s Investor Relations website at https://ir.sbc-holdings.com/

About SBC Medical

SBC Medical Group Holdings Incorporated is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com/en
For more insights and updates from SBC Medical, follow us on LinkedIn.

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as EBITDA and EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes that the non-GAAP financial measures provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company’s operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net income, net income margin, cash flows provided by operating activities, or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.

The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.

For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.


SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED BALANCE SHEETS

	March 31, 2026			December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$	167,305,095		$	163,773,838
Accounts receivable		2,980,193			2,388,021
Accounts receivable – related parties		33,784,532			27,511,730
Inventories		2,323,880			2,792,617
Short-term investments – related parties		313,865			319,193
Finance lease receivables, current – related parties		13,326,150			12,832,355
Income tax recoverable		1,173,913			1,175,510
Customer loans receivable, current		6,659,837			8,705,999
Prepaid expenses and other current assets		10,912,717			11,724,852
Total current assets		238,780,182			231,224,115
Non-current assets:
Property and equipment, net		7,287,369			7,539,392
Intangible assets, net		47,152,285			47,742,888
Long-term investments, net		1,198,583			1,299,366
Equity method investments		20,312,642			20,312,642
Goodwill, net		15,398,049			15,432,061
Finance lease receivables, non-current – related parties		12,548,800			13,746,513
Operating lease right-of-use assets		11,084,198			8,366,569
Finance lease right-of-use assets		392,118			450,874
Deferred tax assets		4,975,629			4,014,294
Customer loans receivable, non-current		3,454,969			4,824,977
Long-term prepayments		705,430			393,270
Long-term investments in MCs – related parties		17,539,564			17,837,293
Other assets		7,189,758			7,263,692
Total non-current assets		149,239,394			149,223,831
Total assets	$	388,019,576		$	380,447,946

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	19,168,072	$		16,988,384
Accounts payable – related parties		527,624			651,463
Bank and other borrowings, current		8,987,118			9,099,046
Advances from customers		1,011,249			1,415,762
Advances from customers – related parties		4,217,057			5,357,221
Income tax payable		8,450,440			8,821,853
Operating lease liabilities, current		5,521,371			4,416,960
Finance lease liabilities, current		118,297			132,946
Accrued liabilities and other current liabilities		11,896,371			11,544,695
Due to related party		2,670,016			2,692,673
Total current liabilities		62,567,615			61,121,003


SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED BALANCE SHEETS — (Continued)

	March 31, 2026			December 31, 2025
Non-current liabilities:
Bank and other borrowings, non-current		31,447,900			33,734,438
Deferred tax liabilities		16,215,816			16,374,832
Operating lease liabilities, non-current		5,731,514			4,136,257
Finance lease liabilities, non-current		93,600			116,527
Other liabilities		1,578,954			1,660,183
Total non-current liabilities		55,067,784			56,022,237
Total liabilities		117,635,399			117,143,240

Commitments and contingencies (Note 19)

Stockholders’ equity:
Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025)		—			—
Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 shares issued, and 102,576,943 shares outstanding as of March 31, 2026 and December 31, 2025)		10,388			10,388
Additional paid-in capital		72,867,424			72,867,424
Treasury stock (at cost, 1,304,308 shares as of March 31, 2026 and December 31, 2025)		(7,749,997	)		(7,749,997	)
Retained earnings		251,756,691			240,448,620
Accumulated other comprehensive loss		(61,541,134	)		(57,294,239	)
Total SBC Medical Group Holdings Incorporated stockholders’ equity		255,343,372			248,282,196
Non-controlling interests		15,040,805			15,022,510
Total stockholders’ equity		270,384,177			263,304,706
Total liabilities and stockholders’ equity	$	388,019,576		$	380,447,946


SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

	For the Three Months Ended March 31,
	2026			2025
Revenues, net – related parties	$	37,955,060		$	45,257,145
Revenues, net		5,105,502			2,071,556
Total revenues, net		43,060,562			47,328,701
Cost of revenues (including cost of revenues from related parties of $124,389 and $3,456,928 for the three months ended March 31, 2026 and 2025, respectively)		12,713,828			9,595,617
Gross profit		30,346,734			37,733,084

Operating expenses:
Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $343,393 and nil for the three months ended March 31, 2026 and 2025, respectively)		12,626,719			13,531,010
Total operating expenses		12,626,719			13,531,010

Income from operations		17,720,015			24,202,074

Other income (expenses):
Interest income		121,369			55,333
Interest expense		(114,806	)		(6,207	)
Foreign currency exchange gain (loss), net		861,678			(1,058,526	)
Other income		491,564			151,328
Other expenses		(223,209	)		(638,733	)
Gain on redemption of life insurance policies		—			8,746,138
Total other income		1,136,596			7,249,333

Income before income taxes		18,856,611			31,451,407

Income tax expense		7,527,591			9,959,457

Net income		11,329,020			21,491,950
Less: net income (loss) attributable to non-controlling interests		20,949			(10,496	)
Net income attributable to SBC Medical Group Holdings Incorporated	$	11,308,071		$	21,502,446

Other comprehensive income (loss):
Foreign currency translation adjustment	$	(4,249,549	)	$	9,808,327
Total comprehensive income		7,079,471			31,300,277
Less: comprehensive income (loss) attributable to non-controlling interests		18,295			(36,832	)
Comprehensive income attributable to SBC Medical Group Holdings Incorporated	$	7,061,176		$	31,337,109

Net income per share attributable to SBC Medical Group Holdings Incorporated
Basic and diluted	$	0.11		$	0.21
Weighted average shares outstanding
Basic and diluted		102,576,943			103,276,637


SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Three Months Ended March 31,
	2026			2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	11,329,020		$	21,491,950
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense		670,434			628,304
Non-cash lease expense		1,420,824			985,184
Provision for (reversal of) credit losses		(31,353	)		25,102
Fair value change of long-term investments		80,301			140,581
Gain on redemption of life insurance policies		—			(8,746,138	)
Gain on disposal of property and equipment		—			(12,375	)
Deferred income taxes		(1,086,473	)		7,016,227
Changes in operating assets and liabilities:
Accounts receivable		(627,606	)		(147,925	)
Accounts receivable - related parties		(6,821,339	)		(295,505	)
Inventories		442,643			(124,279	)
Finance lease receivables - related parties		264,252			(2,779,253	)
Customer loans receivable		3,270,347			4,501,760
Prepaid expenses and other current assets		629,253			(3,150,243	)
Long-term prepayments		31,592			98,164
Other assets		(66,265	)		318,351
Accounts payable		2,484,437			3,235,017
Accounts payable - related parties		(114,689	)		441,481
Notes payables - related parties		—			(548,077	)
Advances from customers		(386,997	)		(328,791	)
Advances from customers - related parties		(1,066,776	)		(2,114,829	)
Income tax payable		(245,955	)		(17,635,239	)
Operating lease liabilities		(1,424,716	)		(1,036,605	)
Accrued liabilities and other current liabilities		543,412			63,764
Other liabilities		(62,408	)		(98,005	)
NET CASH PROVIDED BY OPERATING ACTIVITIES		9,231,938			1,928,621

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(124,995	)		(253,725	)
Prepayments for property and equipment		(423,870	)		(501,253	)
Purchase of long-term investments		—			(635,145	)
Long-term loans to others		—			(12,783	)
Repayments from related parties		—			70,000
Repayments from others		20,840			30,680
Proceeds from disposal of property and equipment		—			323,419
NET CASH USED IN INVESTING ACTIVITIES		(528,025	)		(978,807	)

CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings from related parties		—			15,000
Repayments of bank and other borrowings		(1,782,479	)		(55,873	)
Repayments of finance lease liabilities		(37,278	)		(223,454	)
Repayments to related parties		(22,657	)		(16,053	)
NET CASH USED IN FINANCING ACTIVITIES		(1,842,414	)		(280,380	)

Effect of exchange rate changes		(3,330,242	)		6,342,297

NET CHANGE IN CASH AND CASH EQUIVALENTS		3,531,257			7,011,731
CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD		163,773,838			125,044,092
CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD	$	167,305,095		$	132,055,823

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense	$	114,806		$	6,207
Cash paid for income taxes, net	$	8,848,074		$	20,577,290


SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

	For the Three Months Ended March 31,
	2026		2025
NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment transferred from long-term prepayments	$	68,691	$	125,287
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$	19,664	$	102,599
Finance lease right-of-use assets obtained in exchange for finance lease liabilities	$	—	$	581,129
Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications	$	4,260,931	$	358,358
Payables to related parties in connection with loan services provided	$	—	$	1,922,224
Issuance of common stock as incentive shares	$	—	$	86
Redemption proceeds receivable on life insurance policies	$	—	$	17,735,717


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

SBC MEDICAL GROUP HOLDINGS INCORPORATED
Unaudited Reconciliations of GAAP and Non-GAAP Results

	For the Three Months Ended March 31,
	2026			2025
Total Revenues, net	$	43,060,562		$	47,328,701
Net income attributable to SBC Medical Group Holdings Incorporated		11,308,071			21,502,446
*Net income margin*		26	%		45	%
Income from operations		17,720,015			24,202,074
Depreciation and amortization expense		670,434			628,304
EBITDA		18,390,449			24,830,378
*EBITDA margin*		43	%		52	%

Net income margin is defined as net income attributable to SBC Medical Group Holdings Incorporated divided by total revenues, net. EBITDA is calculated by adding depreciation and amortization expense to income from operations. EBITDA margin is defined as EBITDA divided by total revenues, net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514401130/en/

Contacts

SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of IR Department E-mail: ir@sbc-holdings.com

About Business Wire

Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo